市场调查报告书
商品编码
1491669
裸金属支架市场:按产品、最终用户划分 - 2024-2030 年全球预测Bare-metal Stents Market by Product (Balloon Catheter, Balloon Expendable Stent, Metallic Stent), End Users (Ambulatory Surgical Centers, Cardiac Catheterization Laboratories, Hospitals) - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
裸金属支架市场规模预计2023年为62.3亿美元,预计2024年将达到65.7亿美元,2030年将达到91.7亿美元,复合年增长率为5.66%。
裸金属支架是小型网状金属管,用于医疗手术中以支撑和打开阻塞的动脉。这种类型的支架通常在血管成形术中使用,以治疗冠状动脉疾病引起的动脉狭窄和阻塞。支架恢復血流并防止动脉狭窄。与药物释放型支架不同,裸金属支架没有将药物释放到动脉中的涂层;它们只是由金属材料製成。全球范围内冠状动脉疾病等心血管疾病的增加推动了对裸金属支架的需求。这些疾病仍然是全球死亡的主要原因之一,因此置入术等有效、微创解决方案的需求至关重要,并且持续成长。然而,由于产品召回,裸金属支架面临重大挑战。此类召回通常是由于设备故障或可能对患者造成伤害的安全问题造成的。此外,裸金属支架製造技术的改进使得产品更加精确可靠。雷射切割和改进的生物相容性材料等技术使这些支架越来越耐腐蚀,确保更好的患者治疗效果。
主要市场统计 | |
---|---|
基准年[2023] | 62.3亿美元 |
预计年份 [2024] | 65.7亿美元 |
预测年份 [2030] | 91.7亿美元 |
复合年增长率(%) | 5.66% |
区域洞察
在美洲,美国和加拿大在裸金属支架市场中占有重要地位,反映出其医疗保健系统成熟且心血管疾病盛行率较高。美洲的消费者倾向于微创手术,从而推动了支架需求。最近的投资主要集中在先进技术和降低血管再阻塞的风险。市场渗透率高,品质和品牌声誉受到重视并影响购买行为。另一方面,EMEA市场丰富多样性,严格的监管在塑造市场方面发挥重要作用。最近的欧盟医疗设备法规影响了置入术的实践,强调安全性和有效性。消费者信心高度依赖监管部门的核准,稳定的需求符合医疗保健法规。此外,亚太地区人口众多且老化增加了心血管疾病的盛行率,导致对使用裸金属支架治疗的需求增加。在中国和印度等人口众多的国家,由于城市生活方式的转变以及高血压、糖尿病和肥胖等危险因子的增加,冠状动脉病例数量不断增加。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在裸金属支架市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检查了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可对裸金属支架市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在裸金属支架市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[184 Pages Report] The Bare-metal Stents Market size was estimated at USD 6.23 billion in 2023 and expected to reach USD 6.57 billion in 2024, at a CAGR 5.66% to reach USD 9.17 billion by 2030.
A bare-metal stent is a small, mesh-like metal tube used in medical procedures to support and keep open a blocked artery. This type of stent is often used during a procedure called angioplasty to treat arteries that have been narrowed and blocked due to coronary artery disease. The stent helps restore blood flow and prevents the artery from narrowing. Unlike drug-eluting stents, bare-metal stents do not have a coating that releases medication into the artery; they are simply made of metal materials. The rising prevalence of cardiovascular conditions, such as coronary artery diseases, across the globe acts as a primary driver for the demand for bare-metal stents. As these diseases remain among the leading causes of death worldwide, the need for effective, minimally invasive solutions such as stenting is crucial and continues to grow. However, bare-metal stents have faced significant challenges due to product recalls. Such recalls often stem from issues related to device malfunctions or safety concerns that could potentially harm patients. Moreover, the improvements in manufacturing technologies for bare-metal stents have allowed for more precise and reliable products. With techniques such as laser cutting and improved biocompatible materials, these stents are increasingly effective in resisting corrosion and ensuring better patient outcomes.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 6.23 billion |
Estimated Year [2024] | USD 6.57 billion |
Forecast Year [2030] | USD 9.17 billion |
CAGR (%) | 5.66% |
Regional Insights
In the Americas, the United States and Canada are significant players in the bare-metal stents market, reflecting a mature healthcare system and high incidence rates of cardiovascular diseases. Consumers in the Americas are inclined towards minimally invasive procedures, driving demand for stents. Recent investments have focused on technological advancements and reducing the risk of restenosis. Market penetration is high, and the focus is on quality and brand reputation, influencing purchasing behaviors. On the other hand, the EMEA market is diverse, with regulatory rigor playing a critical role in shaping the market. Recent EU Medical Device Regulations have impacted stenting practices, with a strong emphasis on safety and efficacy. Consumer trust is highly dependent on regulatory approvals, and a steady demand is aligned with healthcare provisions. Moreover, the Asia Pacific region has a large and aging population, which increases the prevalence of cardiovascular diseases and, thus, the demand for interventions involving bare-metal stents. Countries such as China and India, with their vast populations, are seeing higher numbers of coronary artery cases due to shifts towards urban lifestyles and increased occurrences of risk factors such as hypertension, diabetes, and obesity.
Market Insights
The market dynamics represent an ever-changing landscape of the Bare-metal Stents Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Bare-metal Stents Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Bare-metal Stents Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Approves Boston Scientific's AGENT Drug-Coated Balloon, Enhancing Peripheral Artery Disease Treatments
Boston Scientific has received FDA approval for its AGENT Drug-Coated Balloon, a pivotal development in treating peripheral artery disease (PAD). This new medical device is designed to maintain arterial openness and prevent re-blockage, addressing a common issue in PAD therapies. The approval is based on positive outcomes from clinical trials that demonstrated significant improvements in patient conditions with minimal risks. This development marks a significant milestone in vascular medicine, promising enhanced treatment solutions for patients suffering from arterial diseases. [Published On: 2024-03-01]
Kaneka Corporation Enhances Stent Development Capabilities with Acquisition of JMDT
Kaneka Corporation enhanced its position in the medical device sector by acquiring all shares of Japan Medical Device Technology Co., Ltd. (JMDT), a prominent developer and manufacturer of medical devices located in Kamimashiki-gun, Kumamoto. This strategic acquisition positions Kaneka as a fully integrated company in the endovascular catheter market, particularly focusing on coronary artery disease treatments through stenting, a segment worth 30 billion yen in Japan. [Published On: 2023-11-30]
FDA Greenlights Medinol's Innovative Drug-Eluting Coronary Stent
The U.S. Food and Drug Administration (FDA) has officially approved the use of Medinol's latest drug-eluting stent in coronary artery interventions. This state-of-the-art stent integrates medication that actively prevents artery re-blockage, a common issue post-surgery. Key features of the stent include its enhanced design, which significantly betters its flexibility and positioning accuracy compared to traditional bare-metal stents. This approval marks a significant milestone in coronary treatment options, offering enhanced effectiveness and safety, thereby improving patient outcomes in managing coronary artery disease. [Published On: 2023-10-24]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Bare-metal Stents Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Bare-metal Stents Market, highlighting leading vendors and their innovative profiles. These include Abott Laboratories, ACE CARDIOPATHY, B. Braun SE, Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cook Group Incorporated, Medtronic PLC, MeKo Manufacturing e.K., Meril Life Sciences Pvt Ltd., MicroPort Scientific Corporation, Relisys Medical Devices Limited, SLTL Group, STENTYS SA, Stryker Corporation, Terumo Corporation, and Translumina Therapeutics.
Market Segmentation & Coverage